Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 4.16 USD 5.32% Market Closed
Market Cap: 640.4m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one XERS stock under the Base Case scenario is 5.69 USD. Compared to the current market price of 4.16 USD, Xeris Biopharma Holdings Inc is Undervalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

XERS Relative Value
Base Case
5.69 USD
Undervaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.1
P/S
P/S
Price to Sales
3.1
vs History
46
vs Industry
29
Median 3Y
2.4
Median 5Y
2.9
Industry
2.3
Forward
2.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-3
Industry
19.8
Forward
-50.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-3.4
Industry
14.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-5.3
Industry
22.2
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
0
Median 3Y
3.1
Median 5Y
3.8
Industry
1.9
More Details
3.8
EV/S
EV/S
Enterprise Value to Sales
3.8
vs History
42
vs Industry
25
Median 3Y
3
Median 5Y
3.5
Industry
2.4
Forward
2.9
More Details
4.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.6
vs History
46
vs Industry
34
Median 3Y
3.8
Median 5Y
4.4
Industry
4.7
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-3.4
Industry
12
Forward
23.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-3.3
Industry
14.9
Forward
98.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-3.1
Industry
13.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-3
Industry
17.2
More Details
3.1
EV/IC
EV/IC
Enterprise Value to IC
3.1
vs History
33
vs Industry
18
Median 3Y
1.9
Median 5Y
2.1
Industry
1.7
More Details

Multiples Across Competitors

XERS Competitors Multiples
Xeris Biopharma Holdings Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Xeris Biopharma Holdings Inc
NASDAQ:XERS
621.6m USD 3.1 -11.3 -35.5 -22.8
US
Eli Lilly and Co
NYSE:LLY
694B USD 15.4 65.5 38.2 42.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
365.2B USD 4.1 26 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.2 13.9
CH
Roche Holding AG
SIX:ROG
194.4B CHF 3.3 16.9 9.6 11.3
CH
Novartis AG
SIX:NOVN
174.3B CHF 4.1 17.9 10.8 13.9
UK
AstraZeneca PLC
LSE:AZN
155.2B GBP 3.8 28.9 125.6 191.8
US
Merck & Co Inc
NYSE:MRK
200.5B USD 3.1 11.7 8 9.4
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
111.8B EUR 2.5 19.5 8.5 12.5
P/E Multiple
Earnings Growth PEG
US
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Average P/E: 25.6
Negative Multiple: -11.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
65.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
19%
1
CH
Roche Holding AG
SIX:ROG
16.9
16%
1.1
CH
Novartis AG
SIX:NOVN
17.9
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
19.5
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Average EV/EBITDA: 433.1
Negative Multiple: -35.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.6
7%
1.4
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
125.6
9%
14
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.5
6%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Average EV/EBIT: 1 866.4
Negative Multiple: -22.8 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.2
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.9
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
191.8
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.4
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.5
14%
0.9

See Also

Summary
XERS intrinsic value, competitors valuation, and company profile.
DCF Valuation
XERS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
XERS stock valuation using valuation multiples.
Wall Street Estimates
XERS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
XERS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 246,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.